Compare AJG & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AJG | NTRA |
|---|---|---|
| Founded | 1927 | 2003 |
| Country | United States | United States |
| Employees | 706000 | N/A |
| Industry | Specialty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.0B | 45.3B |
| IPO Year | 1995 | 2015 |
| Metric | AJG | NTRA |
|---|---|---|
| Price | $263.81 | $332.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 15 |
| Target Price | ★ $274.60 | $259.07 |
| AVG Volume (30 Days) | 1.3M | ★ 1.3M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | N/A | ★ 0.65 |
| EPS | ★ 4.41 | N/A |
| Revenue | ★ $6,159,600,000.00 | $210,939,000.00 |
| Revenue This Year | $30.53 | $18.08 |
| Revenue Next Year | $9.13 | $19.65 |
| P/E Ratio | $58.87 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $190.75 | $157.43 |
| 52 Week High | $313.55 | $333.56 |
| Indicator | AJG | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 62.86 | 71.73 |
| Support Level | $238.67 | $187.64 |
| Resistance Level | $269.99 | N/A |
| Average True Range (ATR) | 7.13 | 10.88 |
| MACD | 0.24 | 2.40 |
| Stochastic Oscillator | 98.07 | 96.11 |
Founded in 1927 as a one-person agency, Gallagher's primary business is insurance brokerage, with a focus on serving middle-market companies. The company's risk management segment provides third-party claims adjustment to companies that choose to self-insure. Gallagher has about 72,000 employees and generates about a third of its revenue internationally, primarily in Australia, Canada, New Zealand, and the UK.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.